Advent Bioservices joins Unity Campus cohort
Advent’s arrival means that following practical completion in May, 87 per cent of Phase 2 of the Sawston hub will have been let.
The company has committed to a 5+5-year lease of lab and office space within the Cadence building, joining an impressive roster of life science innovators at the campus. It intends to scale across the Cluster and further afield from the growth springboard.
Advent began activity as a cell therapy Contract Development & Manufacturing Organisation (CDMO) in 2016. It is currently managing the development of the state-of-the-art facility for multi-product Good Manufacturing Practice production at Cadence.
This reinforced base will allow scale up of current commercial production and initiate the provision of contract manufacturing services to meet the growing demand for such services in the UK.
At the forefront of revolutionary medicine in which life-threatening diseases are treated using advanced therapy medicinal products, Advent Bioservices supports the development of complex, breakthrough therapies for a globally diverse market.
Mike Scott, President at Advent Bioservices, said: “This space will permit Advent to expand and diversify process development, microbiological testing and quality assurance and quality control services to Biotech and drug development companies working in the cell and gene therapy sector.”
Property investor and developer Howard Group is overseeing the delivery of a bespoke CL2 laboratory fit-out at the Unity Campus development, with Parkeray appointed as the contractor for this project, marking their comprehensive involvement in the fit-out of the entire Cadence building.
The professional team includes 3PM as project managers, CB3 as cost consultants, and Hive for mechanical and electrical services.
With the arrival of Advent and an additional letting also recently completed, the only remaining space in the BREEAM ‘Excellent’ Cadence building is the second floor, offering 10,825 sq ft of high-quality laboratory and office space.
Katherine Friend, Director – Investment and Asset Management, Howard Group, said: "We are thrilled to welcome Advent Bioservices to Unity Campus. Their groundbreaking work in cell therapy aligns perfectly with our vision for Unity Campus as a hub for world-class innovation, breakthroughs, and collaboration in the life sciences sector and further reinforces Unity Campus’ position as a prime destination for pioneering research and development.”
• Prospective occupiers are encouraged to contact the retained agents: Joshua Doble, 07783 771 576 and Edward Hoyle, 07763 203 875 at JLL and Izzy Vyvyan, 07977 757 382 and Tom Mellows, 07870 555 955 at Savills, to discuss this opportunity. Howard Group and Savills are among the sponsors of the annual Business Weekly Awards.